Michela Guardascione

A 12-gene pharmacogenetic panel to prevent adverse drug reactions: an open-label, multicentre, controlled, cluster-randomised crossover implementation study

Jesse J. Swen, Cathelijne H. van der Wouden, Lisanne E. N. Manson et al. · The Lancet · 2023 · 514 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +13

A p53/miR-30a/ZEB2 axis controls triple negative breast cancer aggressiveness

Alessandra di Gennaro, Valentina Damiano, Giulia Brisotto et al. · Cell Death and Differentiation · 2018 · 100 citations · Full text

Medicine, Cancer Biology, Oncology +17

The neutrophil–lymphocyte ratio and its utilisation for the management of cancer patients in early clinical trials

Rajiv Kumar, Elena Geuna, Vasiliki Michalarea et al. · British Journal of Cancer · 2015 · 80 citations · Full text

Medicine, Immunology, Oncology +14

Epigenetic silencing of miR‐200c in breast cancer is associated with aggressiveness and is modulated by ZEB1

Valentina Damiano, Giulia Brisotto, Alessandra di Gennaro et al. · Genes Chromosomes and Cancer · 2016 · 61 citations

Medicine, Genetics, Oncology +17

The Genotype for <i><scp>DPYD</scp></i> Risk Variants in Patients With Colorectal Cancer and the Related Toxicity Management Costs in Clinical Practice

Giuseppe Toffoli, Federico Innocenti, Jerry Polesel et al. · Clinical Pharmacology & Therapeutics · 2018 · 53 citations

Medicine, Oncology, Pharmacology +17